BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 8187346)

  • 1. Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1.
    Hata H; Matsuzaki H; Matsuno F; Sonoki T; Takemoto S; Kuribayashi N; Nagasaki A; Takatsuki K
    Clin Exp Immunol; 1994 May; 96(2):370-5. PubMed ID: 8187346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma.
    Kimlinger T; Witzig TE
    Bone Marrow Transplant; 1997 Mar; 19(6):553-6. PubMed ID: 9085734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma: relationship between light chain isotype suppression, labelling index of plasma cells, and CD38 expression on peripheral blood lymphocytes.
    Joshua DE; Ioannidis R; Brown R; Francis SE; Gibson J; Kronenberg H
    Am J Hematol; 1988 Sep; 29(1):5-11. PubMed ID: 3052044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel membrane antigen selectively expressed on terminally differentiated human B cells.
    Goto T; Kennel SJ; Abe M; Takishita M; Kosaka M; Solomon A; Saito S
    Blood; 1994 Sep; 84(6):1922-30. PubMed ID: 8080996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leu-19 in myeloma--a new role for an old antibody.
    Wetter O; Brandhorst D; Reiter W
    Eur J Cancer; 1990 Apr; 26(4):541. PubMed ID: 1694090
    [No Abstract]   [Full Text] [Related]  

  • 6. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody.
    Stevenson FK; Bell AJ; Cusack R; Hamblin TJ; Slade CJ; Spellerberg MB; Stevenson GT
    Blood; 1991 Mar; 77(5):1071-9. PubMed ID: 1995092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human bone marrow stroma-dependent cell line MOLP-5 derived from a patient in leukaemic phase of multiple myeloma.
    Matsuo Y; Drexler HG; Nishizaki C; Harashima A; Fukuda S; Kozuka T; Sezaki T; Orita K
    Br J Haematol; 2000 Apr; 109(1):54-63. PubMed ID: 10848782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells.
    Yi Q; Dabadghao S; Osterborg A; Bergenbrant S; Holm G
    Blood; 1997 Sep; 90(5):1960-7. PubMed ID: 9292530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma: expression of nucleoside transporters on malignant plasma cells and their relationship to cellular proliferation.
    Petersen AJ; Brown RD; Pope BB; Jamieson GP; Paterson AR; Gibson J; Wiley JS; Joshua DE
    Leuk Lymphoma; 1994 May; 13(5-6):491-9. PubMed ID: 8069194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of early plasma cells in peripheral blood and their clinical significance.
    Harada Y; Kawano MM; Huang N; Mahmoud MS; Lisukov IA; Mihara K; Tsujimoto T; Kuramoto A
    Br J Haematol; 1996 Jan; 92(1):184-91. PubMed ID: 8562394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells.
    Leo R; Boeker M; Peest D; Hein R; Bartl R; Gessner JE; Selbach J; Wacker G; Deicher H
    Ann Hematol; 1992 Mar; 64(3):132-9. PubMed ID: 1373957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of CD38 as target for immunotherapy in multiple myeloma.
    Vooijs WC; Schuurman HJ; Bast EJ; de Gast GC
    Blood; 1995 Apr; 85(8):2282-4. PubMed ID: 7718903
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis.
    McSweeney PA; Wells DA; Shults KE; Nash RA; Bensinger WI; Buckner CD; Loken MR
    Blood; 1996 Jul; 88(2):622-32. PubMed ID: 8695810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.
    Santonocito AM; Consoli U; Bagnato S; Milone G; Palumbo GA; Di Raimondo F; Stagno F; Guglielmo P; Giustolisi R
    Leuk Res; 2004 May; 28(5):469-77. PubMed ID: 15068900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen.
    Schneider U; van Lessen A; Huhn D; Serke S
    Br J Haematol; 1997 Apr; 97(1):56-64. PubMed ID: 9136942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigens on human plasma cells identified by monoclonal antibodies.
    Anderson KC; Park EK; Bates MP; Leonard RC; Hardy R; Schlossman SF; Nadler LM
    J Immunol; 1983 Mar; 130(3):1132-8. PubMed ID: 6401780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Myeloma precursor cells].
    Iwato K; Kawano MM
    Rinsho Ketsueki; 1993 Apr; 34(4):433-8. PubMed ID: 7685432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance.
    Zandecki M; Facon T; Bernardi F; Izydorczyk V; Dupond L; François M; Reade R; Iaru T; Bauters F; Cosson A
    J Clin Pathol; 1995 Jun; 48(6):548-52. PubMed ID: 7545187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19).
    Van Camp B; Durie BG; Spier C; De Waele M; Van Riet I; Vela E; Frutiger Y; Richter L; Grogan TM
    Blood; 1990 Jul; 76(2):377-82. PubMed ID: 1695113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of immature and mature myeloma cells in the bone marrow of human myelomas.
    Kawano MM; Huang N; Harada H; Harada Y; Sakai A; Tanaka H; Iwato K; Kuramoto A
    Blood; 1993 Jul; 82(2):564-70. PubMed ID: 8329711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.